Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model
Introduction
Asthma is a chronic inflammatory disorder of the airways in which different cell types, in particular mast cells, eosinophils, T lymphocytes, neutrophils play a critical role (Nicklas, 1997, Patel, 2014). Asthma is a major cause of chronic morbidity and mortality throughout the world and its prevalence increased considerably over the past 20 years, especially in children (Stevenson and Birrell, 2011, Nagai, 2012, Ezeamuzie et al., 2014). Asthma is a condition characterized by persistent or recurrent airway inflammation, airway hyper-responsiveness (AHR), chronic airway remodeling and various degrees of reversible airflow limitation (Bousquet et al., 2000, Nials and Uddin, 2008, Blume and Davies, 2013). Airway remodeling means persistent changes in airway structure including sub-basement fibrosis, mucus hypersecretion, injury to epithelial cells, smooth muscle hypertrophy and angiogenesis (Global Initiative for asthma Guidelines (GINA), National Asthma Education and Prevention Program (NAEPP), 2007) (DiGiovanni et al., 2009).
The renin angiotensin system (RAS) has been widely implicated in the pathophysiology of cardiovascular disorders. RAS operates via two counteracting arms - ACE1/Ang II/AT1 axis and ACE2/Ang-(1-7)/Mas axis. ACE1 produces Ang II which causes vasoconstriction, proliferation, fibrosis, and inflammation through the activation of the AT1 receptor (Shenoy et al., 2013). ACE2 is major Ang-(1-7)-forming enzyme as it converts Ang II to Ang-(1-7) with 500 folds greater affinity. Ang (1-7) is endogenous ligand for the G protein-coupled receptor Mas and promotes vasodilatation, anti-proliferation, baroreflex sensitivity, potentiation of bradykinin activity and AT1 receptor antagonism (Warner et al., 2007). RAS plays a critical role in pathogenesis of pulmonary hypertension, pulmonary fibrosis in chronic obstructive pulmonary disease (COPD) and acute respiratory distress syndrome (ARDS) (Kuba et al., 2006, Kaparianos and Argyropoulou, 2011). An increased expression of ACE2 and Ang-(1-7) with ACE1 inhibitors (ACEi) or Angiotensin receptor blockers (ARBs) indicates their beneficial role in degrading Ang II locally (Ferreira et al., 2010). ACE2 knockout worsened bleomycin – induced acute lung injury and rhACE2 abrogated it (Rey-Parra et al., 2012). Taken together, ACE2 might be a potential target for the treatment of asthma.
Diminazene aceturate (DIZE) is the most commonly used therapeutic agent for trypanosomiasis in domestic livestock. It is thought to inhibit DNA replication and mitochondrial type II topoisomerases, but as an off-target effect, it increases the activity of the ACE2-mediated angiotensin conversion and this is considered the actual mechanism behind its beneficial effects (Kulemina and Ostrov, 2011). DIZE treatment has been shown to prevent pulmonary hypertension (Shenoy et al., 2013). Here we have hypothesized that the activation of the protective arm of the RAS by novel ACE2 activator — DIZE may attenuate various characteristics of asthma in rat asthma model.
Section snippets
Animals
All the experiments were performed on male adult Wistar rats (200–260 g; 8–9 weeks old). The animals were procured from Central Animal Facility, National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India. The housing of the animals was done as three animals per cage in a room with controlled ambient temperature (22 ± 2 °C), humidity 50 ± 10% and 12 h light/dark cycle. Feed (Pranav Agro Industries, New Delhi) and water were provided ad libitum. All experimental protocols
Statistical analysis
All the data were expressed as mean ± SEM. Means of all groups were compared by one-way analysis of variance (ANOVA) followed by the Tukey's post-test, unless otherwise specified, using GraphPad Prism (v5.01) (GraphPad Software, Inc., CA, USA). The level of significance was set to P < 0.05.
Diminazene aceturate improves morphometry
As compared with control rats, significant loss in body weight was observed in ovalbumin sensitized and challenged (asthmatic) rats. This loss in body weight was prevented by treatment with diminazene aceturate (DIZE). As compared to control rats, asthmatic rats showed significant increase in lungs to body weight ratio and treatment of asthmatic rats with DIZE restored lungs to body weight ratio and prevented airway remodelling. Though absolute heart weight decreased in asthma rats, relative
Discussion
In the present study, we provide evidence that diminazene aceturate (DIZE), an ACE2 activator, corrects the airway inflammation, remodelling, obstruction and responsiveness associated with asthma. The characteristic features of asthma are airway hyperresponsiveness (AHR), eosinophilia, edema, increased mucus production, bronchial inflammation and increased immunoglobulin E levels (Tipnis et al., 2000). Along with the eosinophils and mast cells, T helper type-2 (TH2) cells also contribute to
Conflict of interest
The authors declare no conflicts of interest.
Disclosure statement
The authors have nothing to disclose
Transparency document
Acknowledgements
We wholeheartedly thank National Institute of Pharmaceutical Education and Research, S.A.S. Nagar, India for funding and providing all the amenities for carrying out this research work.
References (46)
- et al.
The potential effect of the angiotensin II receptor blocker telmisartan in regulating OVA-induced airway remodeling in experimental rats
Pharmacol. Rep.
(2015) - et al.
Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo
Eur. J. Pharmacol.
(2013) - et al.
Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes
Eur. J. Pharmacol.
(2005) - et al.
In vitro and ex vivo models of human asthma
Eur. J. Pharm. Biopharm.
(2013) - et al.
Tangeretin suppresses IL-1β-induced cyclooxygenase (COX)-2 expression through inhibition of p38 MAPK, JNK, and AKT activation in human lung carcinoma cells
Biochem. Pharmacol.
(2007) - et al.
Geniposide inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma
Int. Immunopharmacol.
(2013) - et al.
What effect does asthma treatment have on airway remodeling? Current perspectives
J. Allergy Clin. Immunol.
(2011) - et al.
Anti-asthmatic effects of type-A procyanidine polyphenols from cinnamon bark in ovalbumin-induced airway hyperresponsiveness in laboratory animals
Biomed. Aging Pathol.
(2013) - et al.
Angiotensin-converting enzyme 2 in lung diseases
Curr. Opin. Pharmacol.
(2006) - et al.
Prediction of off-target effects on angiotensin-converting enzyme 2
J. Biomol. Screen.
(2011)